Furthermore, encouraging results observed in a clinical trial of the first-in-class IgE antibody, MOv18 IgE, indicate tolerability, with evidence of anticancer activity in a patient with ovarian cancer.17 This evidence concerns the gene IGHE and ovarian carcinoma.